Drug intelligence / Profile preview

VIS1112

Development stage: Preclinical
Lead developer: Visterra
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

VIS1112 is a preclinical-stage monoclonal antibody being developed by Visterra, a subsidiary of Otsuka Pharmaceutical, for the treatment of immune-mediated diseases. The drug was discovered using Visterra's proprietary Hierotope platform, which utilizes computational and structural biology to identify and target specific epitopes (hierotopes) on proteins that are often difficult to address with traditional antibody discovery methods. As of early 2024, the specific biological target and mechanism of action for VIS1112 have not been publicly disclosed by the company.

Targets

TNFSF13 (APRIL)

Beyond the preview

Go deeper on VIS1112.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VIS1112.

Explore the full profile